Over the decade, various surface markers such as folate, epidermal growth factor receptor (EGFR), luteinizing hormone-releasing hormone (LHRH), etc., that are known to express on cancer cells, were explored for developing counter marker functionalized drug carriers to recognize the targeted diseased cells [50,51]. The gene discussed is EGFR; the disease is cancer.